BioVie shares plunge 16.10% despite positive Long COVID subgroup results
AI Summary- BioVie reported topline results from its Phase 2 ADDRESS-LC study of bezisterim in Long COVID patients.
- 41.6% of bezisterim patients reported adverse events, versus 55.9% receiving placebo.
- BioVie announced FDA engagement on a Phase 3 Parkinson’s program earlier in September.